Accuray (ARAY) Reports Q4 Results; Guides Q1, FY12
Tweet
Share
E-mailGet Alerts ARAY Hot Sheet
Price: $0.27 --0%
Revenue Growth %: +2.0%
Financial Fact:
Selling and marketing: 14.32M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +2.0%
Financial Fact:
Selling and marketing: 14.32M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Accuray Incorporated (NASDAQ: ARAY) reported Q4 EPS of ($0.40), which may not compare to the analyst estimate of $0.07 (includes costs related to TomoTherapy deal). Revenue for the quarter came in at $75.2 million versus the consensus estimate of $64.83 million.
Sees Q1 2012 revenue of $80-$85 million, versus the consensus of $93.33 million.
Sees FY2012 revenue of $400-$415 million, versus the consensus of $377.67 million.
Sees Q1 2012 revenue of $80-$85 million, versus the consensus of $93.33 million.
Sees FY2012 revenue of $400-$415 million, versus the consensus of $377.67 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ambarella (AMBA) Tops Q2 EPS by 1c; offers guidance
- Methode Electronics (MEI) Tops Q1 EPS by 2c; offers guidance
- Guidewire Software (GWRE) Tops Q4 EPS by 6c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
